|Bid||0.00 x 900|
|Ask||0.00 x 1000|
|Day's Range||48.19 - 50.09|
|52 Week Range||30.38 - 63.21|
|Beta (5Y Monthly)||0.82|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Applied Genetic's (AGTC) gene therapy candidate shows promise in an early-stage study to treat X-linked retinitis pigmentosa, a rare eye disorder.
We at Insider Monkey have gone over 752 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of September 30th. In this article, we look at what those funds think of Regenxbio Inc (NASDAQ:RGNX) based on that data. […]
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
The drug makers and medical device firms that made the most payments to District physicians and health systems last year include a handful of industry giants with deep local ties.
Regenxbio stock toppled below its 50-day moving average early Wednesday after the U.S. Food and Drug Administration put one of the biotech company's gene therapy candidates on hold.
Regenxbio (RGNX) delivered earnings and revenue surprises of -3.30% and 97.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Bioverativ formed a perfect double bottom, a key chart pattern for growth stock hunters, and broke out ahead of its big 61% gain on news it's being bought by Sanofi.
REGENXBIO Inc. (NASDAQ:RGNX) shareholders might be concerned after seeing the share price drop 23% in the last...
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]
The prospect of RegenxBio’s product could change the game for the roughly 2 million people who suffer from wet age-related macular degeneration in the U.S., Europe and Japan.
Notwithstanding the ESMO conference generating some huge moves in some stocks, last week turned out to be a muted one for biotechs. A few FDA approvals came through, with Puma Biotechnology Inc (NASDAQ: ...
Ultragenyx (RARE) and partner Kyowa Kirin get FDA approval for the label expansion of Crysvita in pediatric patients with X-linked hypophosphatemia.
Does the September share price for REGENXBIO Inc. (NASDAQ:RGNX) reflect what it's really worth? Today, we will...
The FDA grants Orphan Drug and Rare Pediatric Disease designations to Ultragenyx (RARE) and partner GeneTx Biotherapeutics' GTX-102 for the treatment of Angelman Syndrome.
Ultragenyx (RARE) focuses on the development of pipeline candidates. Being a new commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses.
President and CEO of Regenxbio Inc (30-Year Financial, Insider Trades) Kenneth T. Mills (insider trades) sold 15,000 shares of RGNX on 08/19/2019 at an average price of $37.55 a share. Continue reading...